SG11202113265PA - Triple pharmaceutical composition for proteinaceous infection - Google Patents

Triple pharmaceutical composition for proteinaceous infection

Info

Publication number
SG11202113265PA
SG11202113265PA SG11202113265PA SG11202113265PA SG11202113265PA SG 11202113265P A SG11202113265P A SG 11202113265PA SG 11202113265P A SG11202113265P A SG 11202113265PA SG 11202113265P A SG11202113265P A SG 11202113265PA SG 11202113265P A SG11202113265P A SG 11202113265PA
Authority
SG
Singapore
Prior art keywords
proteinaceous
infection
pharmaceutical composition
triple
triple pharmaceutical
Prior art date
Application number
SG11202113265PA
Inventor
Joshua O Atiba
Original Assignee
Joshua O Atiba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/504,723 external-priority patent/US20200000829A1/en
Application filed by Joshua O Atiba filed Critical Joshua O Atiba
Publication of SG11202113265PA publication Critical patent/SG11202113265PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11202113265PA 2019-06-14 2020-06-15 Triple pharmaceutical composition for proteinaceous infection SG11202113265PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962861855P 2019-06-14 2019-06-14
US16/504,723 US20200000829A1 (en) 2018-06-27 2019-07-08 Therapy and prevention of prion protein complex infections
US16/565,242 US10729705B2 (en) 2018-06-27 2019-09-09 Therapy and prevention of prion protein complex infections in non-human animals
PCT/US2020/037787 WO2020252475A1 (en) 2019-06-14 2020-06-15 Triple pharmaceutical composition for proteinaceous infection

Publications (1)

Publication Number Publication Date
SG11202113265PA true SG11202113265PA (en) 2021-12-30

Family

ID=73782140

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113265PA SG11202113265PA (en) 2019-06-14 2020-06-15 Triple pharmaceutical composition for proteinaceous infection

Country Status (9)

Country Link
EP (1) EP3982956A4 (en)
JP (1) JP2022537132A (en)
KR (1) KR20220020832A (en)
CN (1) CN114007609A (en)
BR (1) BR112021025253A2 (en)
CA (1) CA3142164A1 (en)
MX (1) MX2021015266A (en)
SG (1) SG11202113265PA (en)
WO (1) WO2020252475A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
US20040127471A1 (en) * 2002-09-17 2004-07-01 Barry Reisberg Methods of treating age associated memory impairment (AAMI), mild cognitive impairment (MCI), and dementias with cell cycle inhibitors
BRPI0509881A (en) * 2004-04-14 2007-10-16 Warner Lambert Co therapeutic combination for treatment of alzheimer's disease
US20140271923A1 (en) * 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
EA201700052A1 (en) * 2014-08-18 2017-06-30 Фабризио Де Силвестри APPLICATION IN ONE PILLE, TABLET, CAPSULE MINOCYCLINE, ACYCLOGUANOSINE, ATORVASTATIN AND VITAMIN D FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
DE102016208567A1 (en) * 2016-05-19 2017-11-23 Heraeus Medical Gmbh Polymer solution for viscous supplementation
US10350226B1 (en) * 2018-06-27 2019-07-16 Joshua O. Atiba Therapy and prevention of prion protein complex infections

Also Published As

Publication number Publication date
EP3982956A1 (en) 2022-04-20
BR112021025253A2 (en) 2022-04-12
KR20220020832A (en) 2022-02-21
JP2022537132A (en) 2022-08-24
EP3982956A4 (en) 2023-05-03
MX2021015266A (en) 2022-01-18
CA3142164A1 (en) 2020-12-17
CN114007609A (en) 2022-02-01
WO2020252475A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
EP3817722A4 (en) Pharmaceutical compositions comprising meloxicam
EP4045480A4 (en) Pharmaceutical formulations
GB202008961D0 (en) Pharmaceutical composition
EP3946316A4 (en) Cannabidiol pharmaceutical compositions
GB201911517D0 (en) Pharmaceutical composition
EP3868371A4 (en) Novel pharmaceutical composition
IL290469A (en) Oral pharmaceutical composition
EP3881841A4 (en) Pharmaceutical composition
EP3984549A4 (en) Medicinal composition
SG11202113265PA (en) Triple pharmaceutical composition for proteinaceous infection
EP3949952A4 (en) Medicinal composition
EP3914234A4 (en) Pharmaceutical compositions
EP3964264A4 (en) Novel pharmaceutical composition
EP3950058A4 (en) Pharmaceutical composition having favorable stability
EP4011393A4 (en) Pharmaceutical agent for transmucosal administration
EP4081251A4 (en) Pharmaceutical compositions
EP3920909A4 (en) Pharmaceutical compositions comprising meloxicam
EP3845230A4 (en) Pharmaceutical composition for oral administration
FI3908321T3 (en) Pharmaceutical composition
EP3806838A4 (en) Pharmaceutical compositions comprising poh derivatives
EP3841108A4 (en) Pharmaceutical compositions comprising integration-promoting peptides
EP3746080A4 (en) Pharmaceutical formulations
EP4032535A4 (en) Pharmaceutical composition
EP3991750A4 (en) Pharmaceutical composition
EP3957318A4 (en) Pharmaceutical composition